Compile Data Set for Download or QSAR
Report error Found 13 Enz. Inhib. hit(s) with all data for entry = 6150
TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50: 180nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50: 220nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112002(US8623892, 4)
Affinity DataIC50: 510nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50: 960nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50: 5.50E+3nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50: 1.20E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50: 1.90E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50: 2.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50: 2.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50: 3.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C19(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50: 3.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 2C9(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50: 3.90E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50: 5.70E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
Go to US Patent